pistol2
1 mes hace
Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
Press Release | 10/01/2024
JACKSON CENTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wore a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participant data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health.
During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.
Dr. Mark Darrah, CEO of Athena GTX, stated, “The results of this Pilot Study are very encouraging. We met all of our objectives set for this effort, helped the participants with improved health, and discovered ways we can improve the treatment methodology going forward. The proprietary LDX/CBN combination and specialized yoga/meditation positively impacted health and wellness, and the data acquisition system effectively supported participants. We will use what we learned plus feedback from participants to improve the treatment protocol as we proceed to a 100-patient Phase 1 clinical trial.”
Dr. Darrah continued, “As we enter the next programmed step, we wanted to remind any interested parties to consider enrolling in or supporting Phase 1 trials. This is an open invitation to witness first-hand the value and ease of the therapy and its impact.”
William A. Hartman, President and CEO of Halberd Corporation, added, “The results thus far indicate the treatment methodology is having very promising results in the long-term care and treatment of patients suffering from PTSD and associated physical health issues. We remain hopeful that this will result in a widely accepted standard of care.”
Note: The full Athena GTX WatchDawg press release can be accessed via this link.
To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC
0Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
Press Release | 10/01/2024
JACKSON CENTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wore a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participant data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health.
During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.
Dr. Mark Darrah, CEO of Athena GTX, stated, “The results of this Pilot Study are very encouraging. We met all of our objectives set for this effort, helped the participants with improved health, and discovered ways we can improve the treatment methodology going forward. The proprietary LDX/CBN combination and specialized yoga/meditation positively impacted health and wellness, and the data acquisition system effectively supported participants. We will use what we learned plus feedback from participants to improve the treatment protocol as we proceed to a 100-patient Phase 1 clinical trial.”
Dr. Darrah continued, “As we enter the next programmed step, we wanted to remind any interested parties to consider enrolling in or supporting Phase 1 trials. This is an open invitation to witness first-hand the value and ease of the therapy and its impact.”
William A. Hartman, President and CEO of Halberd Corporation, added, “The results thus far indicate the treatment methodology is having very promising results in the long-term care and treatment of patients suffering from PTSD and associated physical health issues. We remain hopeful that this will result in a widely accepted standard of care.”
Note: The full Athena GTX WatchDawg press release can be accessed via this link.
To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC
Aero-man
1 mes hace
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
JACKSON CENTER, Pa., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd’s LDX technology and Athena Corporation’s WatchDawg™ monitoring technology.
Defense Atomics Corporation agreed to use its proprietary CRISPR/Nanotechnology Stem Cell treatment for PTSD/TBI in a minimum of 10 paid veterans in a government pilot study of this cutting-edge protocol. Based on Defense Atomics’ success using CRISPR methodology with overseas patients, this study is intended to substantiate the benefits of this technology in conjunction with Halberd/Athena’s LDX PTSD and TBI/Brain Injury protocol.
https://finance.yahoo.com/news/halberd-partnership-secures-contract-defense-120000500.html
EHRjunkie
2 meses hace
Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System
Jackson Center, PA October 1, 2024 – Halberd Corporation (OTC-PINK: "HALB”) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veteran participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wore a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participant data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health.
During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.
Dr. Mark Darrah, CEO of Athena GTX, stated, “The results of this Pilot Study are very encouraging. We met all of our objectives set for this effort, helped the participants with improved health, and discovered ways we can improve the treatment methodology going forward. The proprietary LDX/CBN combination and specialized yoga/meditation positively impacted health and wellness, and the data acquisition system effectively supported participants. We will use what we learned plus feedback from participants to improve the treatment protocol as we proceed to a 100-patient Phase 1 clinical trial.”
Dr. Darrah continued, “As we enter the next programmed step, we wanted to remind any interested parties to consider enrolling in or supporting Phase 1 trials. This is an open invitation to witness first-hand the value and ease of the therapy and its impact.
William A. Hartman, President and CEO of Halberd Corporation, added, “The results thus far indicate the treatment methodology is having very promising results in the long-term care and treatment of patients suffering from PTSD and associated physical health issues. We remain hopeful that this will result in a widely accepted standard of care.”
pistol2
2 meses hace
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
8:00 AM ET 9/11/24 | GlobeNewswire
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI
JACKSON CENTER, Pa., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd's LDX technology and Athena Corporation's WatchDawg(TM) monitoring technology.
Defense Atomics Corporation agreed to use its proprietary CRISPR/Nanotechnology Stem Cell treatment for PTSD/TBI in a minimum of 10 paid veterans in a government pilot study of this cutting-edge protocol. Based on Defense Atomics' success using CRISPR methodology with overseas patients, this study is intended to substantiate the benefits of this technology in conjunction with Halberd/Athena's LDX PTSD and TBI/Brain Injury protocol.
"While we have observed statistically compelling results in PTSD/TBI management using CRISPR," says CEO Dr. Gabe Vlad of Defense Atomics Corp., "the ability to significantly integrate our treatment protocols with those of Halberd/Athena's medication and monitoring technologies is quite attractive. The WatchDawg monitoring allows us to acquire near real time (NRT) objective data with respect to the administration of CRISPR. From the preliminary data, there's no question that the LDX formulation adds clear adjunctive relief."
Dr. Mark Darrah, of Athena GTX added: "The early results of WatchDawg in LDX therapy are compelling and show that dovetailing therapies of many different forms with real data in brain health studies may hold the key to FDA clearance." He added, "It is much harder to argue against near real time data as opposed to mere recollections of subjective observations alone."
"We look forward to expanded use of LDX, and now that we can actually see the results documented by the WatchDawg technology in military veterans, the benefit in many modalities is limitless," says CEO of Halberd Corporation, William A. Hartman. Hartman continued, "Having commercial packaging of LDX and potentially CRISPR will allow us to market to physician groups even without formal FDA approval under current compounding laws, particularly with our access to, and relationships with, reputable and qualified compounding facilities. This product is useful for myriad disorders from PTSD, anxiety, depression, anger and addiction, to Chronic Covid, Alzheimer's, Chronic Kidney Disease (CKD), diabetes, and others. It has been shown to be remarkably without side-effects. These benefits are unique and extremely important to a successful endeavor. We now have a large quantity of commercially available product (LDX), enabling our team to aggressively market LDX to physician groups, hospitals, rehab centers...and something we haven't discussed and will expand on shortly, animal hospitals and clinics. This finally gives us great potential for real income and a go-to-market capability with actual product. This cannot at this point go directly to consumers, and must go through physicians, which is a potential market. Until then, the physician will be highly incentivized to utilize LDX, so that's a plus."
"While CRISPR is limited in FDA usage in the United States," ATP's Dr. Richard Goulding explains, "the FDA is looking for well-conceived studies to prove efficacy, particularly in areas where little to no other remedy is offered (Right to Try). LDX alone should be a go-to adjunct to all patients with anxiety and PTSD," says Dr. Goulding, adding, "we welcome the opportunity to clinically verify it."
Dr. Vlad added: "I have analyzed the preliminary data offered by the first tranche of patients from the WatchDawg pilot study, and realized that this is clearly the best fit for further research and justification for our CRISPR technology to be used in PTSD and those suffering brain injury. With WatchDawg, we can prove efficacy, or at least support it, all while demonstrating safety and efficacy from initial therapeutic intervention forward. What's exciting to me is the ability to see, thanks to the WatchDawg monitoring technology, real-time therapeutic effects on the individual. With WatchDawg, we would know immediately when something is working or not working, while quantitatively providing real-time data. That's a game changer. We have recently been awarded significant cash contracts and are thrilled to be able to have the funds to engage in this exciting trial with our new partners. Helping veterans suffering from suicidal ideation and PTSD has always been my fondest wish, especially since I am myself a veteran."
Dr. Vlad reports that "Defense Atomics Corp. successfully engineered specialty proprietary stem cells for this endeavor. Essentially what CRISPR does is to collect and utilize the patient's own blood and performs an extremely unique proprietary gene-editing process combined with stem cells to facilitate their goals. Historical results on patients have been quite compelling. I am committed to funding this study with Halberd/Athena. There are still significant regulatory hurdles to overcome, but we have the right personnel on board now to navigate these hurdles. Obviously, the key is to get the FDA the data and information they need to move this treatment forward. We also want veterans suffering from PTSD to have LDX available to them at low cost, so their medical teams can procure it from our existing charity, Stemofhope.com, since we have a commercial quantity of LDX available and all of the high-tech products utilized in the WatchDawg program monitoring platforms."
How large is the Market?
Databridgemarketresearch.com reports the global market for Post-Traumatic Stress Disorder (PTSD) treatments experienced steady growth. As of 2022
Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
squidster
20 horas hace
Kool Aid Man
1 día hace
Huggy Bear
3 semanas hace
retired early
1 mes hace
XenaLives
2 meses hace
Hot Features
Premium
